Data completeness
2/8 — Basic
PLEGINE (phendimetrazine tartrate) by Thayer Medical is clinical pharmacology phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLEGINE (phendimetrazine tartrate) is an oral sympathomimetic amine anorectic agent indicated for the management of exogenous obesity. It works by stimulating the central nervous system and elevating blood pressure to suppress appetite, though the precise mechanism of weight loss is not fully established. The drug is absorbed rapidly with an elimination half-life of approximately 3.7 hours, with renal excretion as the primary elimination route.
Pre-Launch
Pre-launch status indicates a small, focused team building commercial infrastructure; career opportunities center on launch planning, market access, and sales enablement roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance…
Worked on PLEGINE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.